U.S., Jan. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07314164) titled 'Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment' on Dec. 18, 2025.
Brief Summary: This study will assess how well cabozantinib works and how safe it is in adults with a type of cancer called neuroendocrine tumors (NETs).
These tumors can appear in all parts of the body. All participants in this study have already received at least one treatment that affects the whole body to help manage their cancer, but their disease has continued to grow.
The study will take place in regular hospitals and clinics in Germany and Austria.
It will follow about 150 participants who are takin...